Fig. 1: High expression of UHRF1 predicts poor prognosis in AML.
From: Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia
a The qPCR analysis of UHRF1 expression in BM mononuclear cells from AML patients (M2, n = 9; M5, n = 11) and healthy subjects (n = 8). b The Western blotting analysis of UHRF1 in BM cells of AML patients (n = 16), healthy mononuclear cord blood cells (MNCs) (n = 4) and CD34+ HSPCs (n = 4). c Quantification of the Western blotting analysis for b. d The microarray analysis of UHRF1 in CD34+ leukemia cells and LSCs of AML patients from GSE76009. (CD34+, n = 110; CD34‒, n = 117; n-LSC+, n = 138; n-LSC‒, n = 89). e The differential expression of UHRF1 in mononuclear BM or PB cells of AML patients [t(15;17), n = 87; Inv(16), n = 77; t(11q23), n = 88; t(8;21), n = 98)] and HSCs in healthy subjects (HSC, n = 6). Data were obtained from the microarray analysis of bloodpool. The samples were normalized and batch corrected using ComBat for full completeness of the dataset. PCA analysis and gene signature values were then calculated. f The event free survival of patients with t(8;21) leukemia was stratified by UHRF1 expression into UHRF1 high (n = 27) and low (n = 51) groups. The survival days (UHRF1 high: 510 days; UHRF1 low: 1067 days) mean the date of the event occurrence in AML patients such as relapse and drug resistance, etc. g The differential expression of UHRF1 in the relapsed (n = 14) and non-relapsed (n = 35) t(8;21) leukemia patients. h MLL-AF9 localizes at the promoter region of Uhrf1 in the CUT&Tag analysis of 32D cells transduced with MLL-AF9. i AML1-ETO, HEB, E2A and LMO2 colocalize at the gene body region of UHRF1 in the ChIP-seq analysis of Kasumi-1 cells. j, k The mouse BM cells transduced with MLL-AF9 (j) or AE9a (k) were analyzed. The anti-Uhrf1, anti-MLL1, anti-HA and anti-Actin antibodies were used for the Western blotting analysis. l, m Knockdown of AML1-ETO in Kasumi-1 cells decreased the mRNA (l) and protein (m) levels of AML1-ETO and Uhrf1. The anti-Uhrf1, anti-ETO and anti-Actin antibodies were used for the Western blotting analysis. Data are all presented as means ± SD. Statistical analyses were performed using Student’s unpaired t-test for a, c–e, g, l. The expression values for e were log2 transformed. Statistical significance was evaluated by log-rank test for f. The mRNA expression for g were statisticed by FPKM from RNA-seq. *P < 0.05; **P < 0.01; ***P < 0.001.
